Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4834 Pages (Click to Jump) V   1 2 3 4 > »    
Reply to this topic

post Posted: Today, 07:34 PM
  Quote Post

Posts: 577
Thanks: 2366

One of the clinical trials that I have been most
interested in throughout the years is
CUV011 with 200 participants aimed to evaluate
Scenesse in AK/SCC in organ transplant recipients.

It had an end date in 2012 but results were never reported.
I’ve wondered for a long time if it was classic Clinuvel behavior
burying bad results or if there was indeed a strategic reason
for not reporting.

The principal investigator was / is Günther Hofbauer and in this article from
December, 2014 he states, that “studies are currently underway,” suggesting that
the trial was ongoing at that time.

With the renewed focus on DNA repair and general protection against skin
cancers the AK/SCC OTR trial could be a centerpiece, I think.

Was it a failure, was it a success, was it still ongoing in 2014, is it still ongoing
today, was it finished and just waiting to be published at the right moment ?
Attached thumbnail(s)
Attached Image


Said 'Thanks' for this post: PortugueseMan  IntiRaymi  
the near future
post Posted: Today, 05:48 PM
  Quote Post

Posts: 514
Thanks: 462

In Reply To: garthyd's post @ Today, 04:58 PM

As you said, it can not last

SP is a joke at the moment, very cheap

Big new investor might join the party soon

post Posted: Today, 04:58 PM
  Quote Post

Posts: 147
Thanks: 217

In Reply To: the near future's post @ Today, 04:36 PM

In only a month, our 12 month low will be $21......which its pretty unfathomable to think we could be at 12 month lows after FDA approval......It can't last.

the near future
post Posted: Today, 04:36 PM
  Quote Post

Posts: 514
Thanks: 462

In Reply To: garthyd's post @ Today, 03:16 PM

Nobody is selling, rather people are buying at this low sp price

the short sellers seems that they sold most of their shares, waiting to buy back

I hope we bottomed now, and short squeese will happen with any upcoming news

Said 'Thanks' for this post: waz  
post Posted: Today, 03:16 PM
  Quote Post

Posts: 147
Thanks: 217

Gotta be one of our lowest volume trading days in months?

Fortescue Bullro...
post Posted: Today, 11:55 AM
  Quote Post

Posts: 120
Thanks: 149

Just ordered 2k at market. Very encouraged by all I am reading the last few days, and LHFUD receding in the rear view mirror. Thanks sharelooker, waz and all here.
Got them at 26.038.

Said 'Thanks' for this post: the near future  Alaaf  waz

Share Cafe Sentifi Top themes and market attention on:

post Posted: Today, 11:48 AM
  Quote Post

Posts: 359
Thanks: 66

Friday 6th Dec on the ASX only 50,530 of the total volume of 164,852 shares sold were short sales. Some profit taking maybe?

post Posted: Today, 10:16 AM
  Quote Post

Posts: 173
Thanks: 568

New director buying shares on market - bought at $27.43. Would be good to see more director buying on-market. Don't stop now.

Said 'Thanks' for this post: scipio79  Farleap11  Alaaf  IntiRaymi  
post Posted: Today, 09:03 AM
  Quote Post

Posts: 173
Thanks: 568

In Reply To: IntiRaymi's post @ Today, 06:14 AM

My read is that CUV has in recent months sought to update and finalise this patent and a separate XP related patent. There appears to be some finalisation of the compound description in particular plus refinement over claims.

There is wide coverage in application and while these patents have been in progress some time this all seems to be a precursor to CUV getting cracking on the wider application of afamelanotide now that FDA approval is in place.

Finer points in PW's AGM and other recent monologues indicate the real action with the compound is now moving ahead. I am expecting this to occur on all fronts - Vitiligo, VP, XP and in particular DNA repair, where once ethics approval is obtained from the FDA the 20 person clinical trial can be agreed upon, populated and commence. I believe CUV already know the answer but obviously need the programmed clinical evidence to obtain the further approval needed for DNA repair compounds in treatment and prevention of skin cancers.

Said 'Thanks' for this post: polyphemus  LJS  Alaaf  IntiRaymi  
post Posted: Today, 06:14 AM
  Quote Post

Posts: 105
Thanks: 99

In Reply To: waz's post @ Dec 7 2019, 10:36 AM

I’ve been reading the ...text intended for grant - and trying to make sense of it.

Is this patent for extensions to the chemical formulation of afamelanotide and for extensions to the uses/indications of it?

I notice they talk about testing and efficacy in some different compounds. Are these compounds for which they’ve received patents something that we may see tested/brought to market?

I’m really not sure what I’m asking just wondering what the real significance of this patent being granted is?


4834 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.